Which statement best describes typical and atypical pathogens in adult CAP and how empiric therapy is chosen?

• A. Typical: Streptococcus pneumoniae and Haemophilus influenzae; Atypical: Mycoplasma; Therapy with beta-lactam alone for all.
• B. Typical: Streptococcus pneumoniae and Haemophilus influenzae; Atypical: Mycoplasma, Chlamydophila, Legionella; Therapy may cover both in many patients (macrolide or doxycycline for healthy; beta-lactam plus macrolide or respiratory fluoroquinolone for others)
• C. Typical: Nocardia; Atypical: Legionella; Therapy with antifungals.
• D. None of the above.

Answer: (B)

In adult community-acquired pneumonia, pathogens are grouped as typical and atypical, and empiric therapy is chosen to cover both because a patient’s presentation can be similar regardless of the organism and certain pathogens aren’t well-treated by beta-lactams alone. Typical pathogens like Streptococcus pneumoniae and Haemophilus influenzae are the classic culprits that cause lobar consolidation and are generally susceptible to beta-lactam antibiotics that target cell wall synthesis. Atypical pathogens—Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella species—have different biology (Mycoplasma lacks a cell wall; Legionella and Chlamydophila are intracellular), so they often don’t respond to beta-lactams alone and require antibiotics such as macrolides, doxycycline, or respiratory fluoroquinolones.

Thus, treatment plans often aim to cover both groups. In healthy outpatients, a macrolide or doxycycline is commonly used because these drugs cover atypicals and many typical pathogens. In patients with comorbidities or risk factors for resistant organisms, a beta-lactam plus a macrolide (for example, amoxicillin-clavulanate with a macrolide) or a respiratory fluoroquinolone alone is preferred to ensure coverage of both typical and atypical organisms.